A highly sensitive peptide substrate for detecting two Aβ-degrading enzymes: Neprilysin and insulin-degrading enzyme

Journal of Neuroscience Methods

Volumn 190, Issue 1, 2010, Pages 57-62

  Chen, Po Ting ^a,b   Liao, Tai Yan ^b   Hu, Chaur Jong ^c   Wu, Shu Ting ^c   Wang, Steven S S ^a   Chen, Rita P Y ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

A ; Alzheimer; Amyloid; Digestion; Fluorescence; Insulin degrading enzyme; Neprilysin; Quench

Indexed keywords

AMYLOID BETA PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN CONVERTING ENZYME; GELATINASE B; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PLASMIN; PROTEINASE; SOMATOSTATIN; STROMELYSIN; PEPTIDE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SENSITIVITY ANALYSIS; AMINO ACID SEQUENCE; CHEMISTRY; FLUORESCENCE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KINETICS; MASS SPECTROMETRY; METABOLISM; PROCEDURES; WESTERN BLOTTING;

AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORESCENCE; FLUOROMETRY; HUMANS; INSULYSIN; KINETICS; NEPRILYSIN; PEPTIDES; SOMATOSTATIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTRATE SPECIFICITY; AMYLOID BETA-PEPTIDES;

EID: 77953724946     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.04.024     Document Type: Article

References (39)

1. Barnes K., Turner A.J., Kenny A.J. Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase A (angiotensin converting enzyme) in the pig brain: a study using subcellular fractionation and electron microscopic immunocytochemistry. J Neurochem 1992, 58:2088-2096.
2. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88:1337-1342.
3. Caccamo A., Oddo S., Sugarman M.C., Akbari Y., LaFerla F.A. Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders. Neurobiol Aging 2005, 26:645-654.
4. Carpentier M., Robitaille Y., DesGroseillers L., Boileau G., Marcinkiewicz M. Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002, 61:849-856.
5. Carson J.A., Turner A.J. β-Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?. J Neurochem 2002, 81:1-8.
6. Carvalho K.M., Boileau G., Camargo A.C.M., Juliano L. A highly selective assay for neutral endopeptidase based on the cleavage of a fluorogenic substrate related to Leu-Enkephalin. Anal Biochem 1996, 237:167-173.
7. Chagas J.R., Juliano L., Prado E.S. Intramolecularly quenched fluorogenic tetrapeptide substrates for tissue and plasma kallikreins. Anal Biochem 1991, 192:419-425.
8. Chen S., Zhang X.J., Li L., Le W.D. Current experimental therapy for Alzheimer's disease. Curr Neuropharmacol 2007, 5:127-134.
9. Chersi A., Ferracuti S., Falasca G., Butler R.H., Fruci D. Assembly and selective " in synthesis"labeling of quenched fluorogenic protease substrates. Anal Biochem 2006, 357:194-199.
10. Duckworth W.C., Bennett R.G., Hamel F.G. Insulin degradation: progress and potential. Endocr Rev 1998, 19:608-624.
11. Eckman E.A., Eckman C.B. Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 2005, 33:1101-1105.
12. El-Amouri S.S., Zhu H., Yu J., Marr R., Verma I.M., Kindy M.S. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 2008, 172:1342-1354.
13. Evin G., Weidemann A. Biogenesis and metabolism of Alzheimer's disease Aβ amyloid peptides. Peptides 2002, 23:1285-1297.
14. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003, 100:4162-4167.
15. Farris W., Schutz S.G., Cirrito J.R., Shankar G.M., Sun X., George A., et al. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 2007, 171:241-251.
16. Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J Clin Invest 2005, 115:1121-1129.
17. Hardy J.A., Higgins G.A. Alzheimers-disease-the amyloid cascade hypothesis. Science 1992, 256:184-185.
18. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
19. Hersh L.B., Rodgers D.W. Neprilysin and amyloid β peptide degradation. Curr Alzheimer Res 2008, 5:225-231.
20. Hsu R.L., Lee K.T., Wang J.H., Lee L.Y., Chen R.P. Amyloid-degrading ability of nattokinase from Bacillus subtilis natto. J Agric Food Chem 2009, 57:503-508.
21. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., et al. Metabolic regulation of brain Aβ by neprilysin. Science 2001, 292:1550-1552.
22. Iwata N., Higuchi M., Saido T.C. Metabolism of amyloid-β peptide and Alzheimer's disease. Pharmacol Ther 2005, 108:129-148.
23. Jakob-Roetne R., Jacobsen H. Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed 2009, 48:3030-3059.
24. Kanemitsu H., Tomiyama T., Mori H. Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003, 350:113-116.
25. Kim M., Hersh L.B., Leissring M.A., Ingelsson M., Matsui T., Farris W., et al. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem 2007, 282:7825-7832.
26. Ling Y., Morgan K., Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int J Biochem Cell B 2003, 35:1505-1535.
27. Llorens C., Malfroy B., Schwartz J.C., Gacel G., Roques B.P., Roy J., et al. Enkephalin dipeptidyl carboxypeptidase (enkephalinase) activity: selective radioassay, properties, and regional distribution in human brain. J Neurochem 1982, 39:1081-1089.
28. Marr R.A., Guan H., Rockenstein E., Kindy M., Gage F.H., Verma I., et al. Neprilysin regulates amyloid β peptide levels. J Mol Neurosci 2004, 22:5-11.
29. Miners J.S., Kehoe P.G., Love S. Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. J Neurosci Methods 2008, 169:177-181.
30. Miners J.S., Verbeek M.M., Rikkert M.O., Kehoe P.G., Love S. Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods 2008, 167:229-236.
31. Nalivaeva N.N., Fisk L.R., Belyaev N.D., Turner A.J. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2008, 5:212-224.
32. Rafii M.S., Aisen P.S. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009, 7:7.
33. Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S.M., et al. Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation. Nat Med 2005, 11:434-439.
34. Turner A.J., Nalivaeva N.N. New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. Int Rev Neurobiol 2007, 82:113-135.
35. Vardy E.R.L.C., Catto A.J., Hooper N.M. Proteolytic mechanisms in amyloid-β metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med 2005, 11:464-472.
36. Wang D.S., Iwata N., Hama E., Saido T.C., Dickson D.W. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem Biophys Res Commun 2003, 310:236-241.
37. Wang Y.J., Zhou H.D., Zhou X.F. Clearance of amyloid-β in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 2006, 11:931-938.
38. Waxman L., Goldberg A.L., Protease La the lon gene product, cleaves specific fluorogenic peptides in an ATP-dependent reaction. J Biol Chem 1985, 260:12022-12028.
39. Zhao Z., Xiang Z., Haroutunian V., Buxbaum J.D., Stetka B., Pasinetti G.M. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 2007, 28:824-830.